Corcept Therapeutics Faces Shareholder Litigation Over Alleged FDA Disclosure Failures
Event summary
- Kuehn Law is investigating Corcept Therapeutics for potential breaches of fiduciary duties related to FDA approval disclosures.
- A federal securities lawsuit alleges Corcept failed to disclose FDA concerns about the adequacy of its clinical development program for relacorilant.
- Relacorilant's New Drug Application faced material risk of rejection, according to the lawsuit.
- Shareholders who purchased CORT prior to October 31, 2024, are encouraged to contact Kuehn Law.
The big picture
This litigation highlights the growing scrutiny on biopharmaceutical companies regarding transparency in regulatory communications. The case underscores the risks associated with overstating the likelihood of FDA approval, particularly for lead product candidates like relacorilant. The outcome could set a precedent for how other firms manage disclosures related to clinical development programs.
What we're watching
- Regulatory Risk
- How the FDA's concerns about relacorilant's clinical development program will impact Corcept's regulatory strategy.
- Litigation Impact
- Whether the shareholder litigation will lead to significant financial or reputational damage for Corcept.
- Market Reaction
- The pace at which investor confidence in Corcept's leadership and disclosure practices may be restored.